ABCL vs IVF

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 21, 2026

ABCL

40.3
AI Score
VS
ABCL Wins

IVF

37.8
AI Score

Investment Advisor Scores

ABCL

40score
Recommendation
HOLD

IVF

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABCL IVF Winner
Revenue 12.36M 1.64M ABCL
Net Income -98.59M -17.40M IVF
Net Margin -797.5% -1063.0% ABCL
Operating Income -120.30M -1.20M IVF
ROE -11.0% 64.0% IVF
ROA -7.5% -54.8% ABCL
Total Assets 1.31B 31.74M ABCL
Cash 120.06M 840,407 ABCL
Current Ratio 12.77 0.08 ABCL
Free Cash Flow -13.56M -3.56M IVF

Relative Price Performance (Last 90 Days)

ABCL 1M: +99.6% · 3M: +120.2% IVF 1M: +3.9% · 3M: -32.9%

Current Technical Phase

ABCL

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (21.0% over 20 days), RSI 74

RSI (14): 73.9 · Price: $11.32

IVF

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.8 · Price: $1.06

Fundamentals Snapshot

Metric ABCL IVF
Market Cap
Forward P/E -15.8 -0.1
Trailing P/E 0.0
Revenue (TTM)
Revenue Growth -0.8% 0.2%
Gross Margin -2.0% 0.4%
Operating Margin -15.5% -0.6%
EPS -0.52 353.17
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, ABCL is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.